- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06588504
Onderzoeksstudie in Japan om Dasiglucagon te vergelijken met glucagon bij de behandeling van zeer lage bloedsuikerspiegels bij Aziatische volwassenen met diabetes type 1 en testen van Dasiglucagon voor dezelfde aandoening bij Japanse adolescenten
Een fase 3, gerandomiseerde, open-label, cross-over studie om de klinische werkzaamheid en veiligheid van Dasiglucagon versus glucagon te bevestigen voor de behandeling van ernstige hypoglykemie bij Aziatische volwassenen met type 1 diabetes (T1D), inclusief een onderzoek naar Dasiglucagon bij een Japanse adolescent Cohort
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low blood sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Fukuoka, Japan, 812-0025
- Hakata Clinic
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- For Adults: Asian male or female; For Adolescents: Japanese male or female.
- Age at the time of signing the informed consent:
For Adults: Age 18-75 years (both inclusive):
For Adolescents: Age 12-15 years (both inclusive).
- Diagnosed with T1D greater than (>)1 year before screening.
- Glycated haemoglobin (HbA1c) less than (<)10.0 percentage (%) (86 millimoles per mole [mmol/mol]) as assessed by subcontracted laboratory by the site on the day of screening.
- For adults: BMI between 18.5 and 29.9 kilogram per meter square (kg/m2) (both inclusive).
For adolescents: Body weight greater than or equal to (≥) 33.4 kilograms (kg).
- Treated with stable insulin treatment (based on the investigator's discretion preferably no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening.
- For Japanese participants: Japanese passport or equivalent For non-Japanese participants: Asian (non- Japanese passport or equivalent).
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products (glucagon or its derivatives).
- Exposure to an investigational medicinal product (IMP) within 30 days or 5 times the half-life of the IMP (if known), whichever is longest before screening.
- Severe hypoglycaemia in the last month prior to screening.
- Hospitalisation for diabetic ketoacidosis (DKA) in the last month prior to screening.
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).
- History of epilepsy or seizure disorder.
- Known presence or history of pheochromocytoma (i.e., adrenal gland tumour) or insulinoma (i.e., insulin-secreting pancreas tumour).
- Clinically significant abnormal electrocardiogram (ECG) at screening as evaluated by investigator.
- Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
As declared by the participant or in the medical records.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Adult Cohort: Dasiglucagon then Glucagon
Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit. |
Participants will receive s.c. injection of dasiglucagon. |
|
Experimenteel: Adult Cohort: Glucagon then Dasiglucagon
Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit. |
Participants will receive s.c. injection of dasiglucagon. Participants will receive i.m. injection of glucagon. |
|
Experimenteel: Adolescent Cohort: Dasiglucagon
Participants will receive a single s.c. injection of dasiglucagon. |
Participants will receive s.c. injection of dasiglucagon. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline
Tijdsspanne: Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
|
This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter [mmol/L]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)
Tijdsspanne: Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
|
This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection. |
Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)
Tijdsspanne: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)
Tijdsspanne: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)
Tijdsspanne: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
|
|
Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection
Tijdsspanne: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
|
This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
|
|
Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection
Tijdsspanne: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
|
This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
|
|
AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection
Tijdsspanne: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
|
This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms. |
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
|
|
Cmax: Maximum Observed Plasma Dasiglucagon Concentration
Tijdsspanne: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
|
This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms. |
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
|
|
Number of Adverse Events (AEs) for All Participants in Each Arms
Tijdsspanne: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
|
This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP. |
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
|
|
Number of Hypoglycaemic Episodes for All Participants in Each Arms
Tijdsspanne: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
|
This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); <3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; < 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. |
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Metabole ziekten
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Glucosemetabolismestoornissen
- Suikerziekte
- Voedings- en stofwisselingsziekten
- Diabetes mellitus, type 1
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Peptide hormonen
- Peptiden
- Aminozuren, peptiden en eiwitten
- Pancreashormonen
- Proglucagon
- Glucagon
- dasiglucagon
Andere studie-ID-nummers
- NN9515-7675
- U1111-1300-1855 (Andere identificatie: World Health Organization (WHO))
- jRCT2071240050 (Register-ID: Japan Registry for Clinical Trials (jRCT))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .